< Back to previous page
Researcher
Michel Delforge
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Member
From1 Jan 2021 → Today - Stem Cell and Developmental Biology (Division)
Member
From1 Apr 2013 → 31 Dec 2020 - Faculty of Medicine (Faculty)
Member
From1 Oct 2000 → 30 Sep 2002
Projects
11 - 19 of 19
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myelomaFrom1 Jan 2019 → 31 Dec 2022Funding: Foundations, funds and other with scientific goal
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myelomaFrom10 Sep 2018 → 31 Oct 2023Funding: FWO Strategic Basic Research Grant
- Clin-IC: Medtech solutions for patientsFrom1 May 2018 → TodayFunding: IOF - mandates, IOF - Industrial Research Fund
- Mass cytometry by time-of-flight: next-generation flow cytometry for multiplexed single cell analysisFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
- In search of novel working mechanisms of proteasome inhibitors in multiple myelomaFrom1 Oct 2015 → 13 Nov 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- MSC/MAPC-based modulation of the immune/inflammatory mechanisms underlying bone marrow failure in MDS.From1 Jan 2013 → 31 Dec 2014Funding: Private funding of national origin - undefined
- MSC/MAPC-based modulation of the immune/inflammatory mechanisms underlying bone marrow failure in MDS.From1 Jan 2012 → 31 Dec 2015Funding: FWO Humanitarian research project Stand up against Cancer
- Characterization of molecular mechanisms that enhance hematopoietic reconstitution of hematopoietic stem cells (HSC).From1 Jan 2011 → 31 Dec 2016Funding: FWO research project (including WEAVE projects)
- Stem Cell Program.From1 Nov 2010 → 31 Oct 2017Funding: BOF - Concerted Research Project from 1994
Publications
1 - 10 of 265
- Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.(2024)
Authors: Michel Delforge
Pages: 194 - 202 - Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.(2024)
Authors: Michel Delforge
Pages: e216 - e227 - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.(2024)
Authors: Michel Delforge
Pages: 301 - 313 - The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)(2023)
Authors: Michel Delforge
- Effects of Idecabtagene Vicleucel ( Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial(2023)
Authors: Michel Delforge
- Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3(2023)
Authors: Michel Delforge
- Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3(2023)
Authors: Michel Delforge
- Effects of Idecabtagene Vicleucel ( Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial(2023)
Authors: Michel Delforge
- Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion plus MoMMent Studies(2023)
Authors: Michel Delforge
- An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma(2023)
Authors: Michel Delforge
Pages: 1864 - 1869
Patents
1 - 2 of 2
- Cell therapy for myelodysplastic syndromes (Inventor)
- CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES (Inventor)